Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

Summary

This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.

Timeline

Start

2021-06-29

Primary completion

2022-06-30

Completion

2022-06-30

Outcome

Outcome not reported

Stopped: “Sponsor is stopping the study to focus company resources on other development programs.”

Drugs

Indications